Boston Scientific forecasts Q4 2026 net sales decline of 1%-3%
Bitget2026/10/28 10:38- Boston Scientific forecasts full-year 2026 adjusted earnings of $3.16-$3.18 per share.
- Annual reported sales growth is projected at approximately 4.25%; organic growth is expected at approximately 3.75%.
- Fourth-quarter 2026 reported sales are expected to decline 1%-3% year over year, matching the organic sales outlook.
- Adjusted earnings are forecast at $0.77-$0.79 per share for the quarter.
- Third-quarter 2026 sales rose 1.5% to $5.14 billion, with several businesses affected by a cyber incident.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ripple's Dubai Event Presence Gets High-Profile Boost From Emirates Chairman
Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"
Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.
SpaceX (SPCX.US) undergoes board changes: Google executive departs, Tesla merger evaluation underway.
SpaceX (SPCX.US) announced on Friday that Don Harrison has resigned from the company's board of directors.
Crypto prices
More
